PubMed · 1994 · 64 citations · 0 references
MedicinePharmacologyPsychiatryDementiaNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDementia PharmacotherapyNeurodegenerative Disease PharmacotherapySerotonergic PharmacologyAntidepressant MedicationsAntidepressant Use In DementiaDouble-blind TrialsMood EffectsPharmacological Treatment Of DementiaPilot Study DesignSerotonergic NeurotransmissionSerotonin Pharmacodynamics
BACKGROUND: Central serotonin depletion may contribute to the anxiety, restlessness, irritability, and affective disturbance seen in a variety of psychiatric conditions, particularly dementia of the Alzheimer's type (DAT) in which brain concentrations of both 5-hydroxytryptamine (5-HT) and its 5-hydroxyindoleacetic acid (5-HIAA) metabolite are reduced. METHOD: Trazodone, a serotonergic antidepressant with alpha 2-adrenergic blocking activity, was administered to 13 patients with DAT in an open 10-week pilot study at a dose of 25 mg t.i.d. Behavioral and affective disturbance was assessed pretreatment and posttreatment using semistructured interview and Jouvent's Depressed Mood and Gottfries-Brane-Steen scales. RESULTS: Irritability, anxiety, restlessness, and affective disturbance were all decreased (p < .05). No side effects were observed. Mean Mini Mental State scores were unaffected by treatment. CONCLUSION: The hypothesis that trazodone corrects behavioral and affective disturbance induced by serotonin depletion in DAT requires confirmation in a double-blind placebo-controlled trial.